Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
By Dr. Matthew Watson
SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants.
Here is the original post:
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
Related Post
- Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates - March 31st, 2025
- HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results - March 31st, 2025
- Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - March 31st, 2025
- Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors - March 31st, 2025
- Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX - March 31st, 2025
- Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results - March 31st, 2025
- HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress - March 31st, 2025
- Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates - March 31st, 2025
- Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension... - March 31st, 2025
- Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery... - March 31st, 2025
- Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025 - March 31st, 2025
- Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress - March 31st, 2025
- First Three Children to Commence Treatment With Ryoncil® - March 31st, 2025
- BioVersys Announces Important BV100 Patent Granted by Chinese Patent Office - March 31st, 2025
- Opthea Announces Decision to Discontinue Wet AMD Trials - March 31st, 2025
- Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the... - March 31st, 2025
- Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA - March 31st, 2025
- AAVantgarde and TIGEM Publish Groundbreaking Research in Science Advances - March 31st, 2025
- NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - March 31st, 2025
- Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting - March 22nd, 2025
- FDA Approves New Prostate Cancer Imaging Agent Gozellix® - March 22nd, 2025
- OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category - March 22nd, 2025
- 23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test - March 22nd, 2025
- Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - March 22nd, 2025
- Pharmaceutical industry delivers value proposition to Finnish Government: billions to be invested by 2030 - March 22nd, 2025
- BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 - March 22nd, 2025
- PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington - March 22nd, 2025
- Bright Green Corporation Announces the next steps for the completion of its restructuring plan - March 22nd, 2025
- Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million - March 22nd, 2025
- Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - March 22nd, 2025
- Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX - March 22nd, 2025
- Impact Biomedical Inc. Announcement Stock Activity/Pricing - March 22nd, 2025
- I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - March 22nd, 2025
- Better Choice Company Shareholders Overwhelmingly Approve Acquisition of SRx Health Solutions and Related Proposals - March 22nd, 2025
- Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - March 22nd, 2025
- Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting... - March 22nd, 2025
- Atea Pharmaceuticals Issues Statement Regarding Director Nominations - March 22nd, 2025
- Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. - March 22nd, 2025
- Arialief Reviews (Is It Safe And Legit To Use?) What Do Arialief Consumer Reports Say About Its Efficacy? - March 22nd, 2025
- Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of... - March 11th, 2025
- BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System - March 11th, 2025
- PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands - March 11th, 2025
- Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38 - March 11th, 2025
- Transactions under Novonesis’ share buyback program - March 11th, 2025
- Dogecoin Cash, Inc. ($CBDS) Expands into Meme Coin Market with Formation of MEME COINS Inc. - March 11th, 2025
- Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory... - March 11th, 2025
- Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO - March 11th, 2025
- MSInsight Announces €1.6 Million in Seed Fundraising to Revolutionize MSI Cancer Diagnosis - March 11th, 2025
- Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025 - March 11th, 2025
- Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 - March 11th, 2025
- Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences - March 11th, 2025
- Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - March 11th, 2025
- Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update - March 11th, 2025
- CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies - March 11th, 2025
- Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs - March 11th, 2025
- Druid City Vital Care Recognized at Vital Care Infusion Services Annual Conference - March 11th, 2025
- Abpro Statement on the Departure of Former CEO Ian Chan - March 11th, 2025
- Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health... - March 11th, 2025
- ProstaVive Reviews (Consumer Report Analysis) Is It Safe And Effective For Healthy Prostate Function? - March 11th, 2025
- TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of adult patients with moderately to severely active ulcerative colitis - March 1st, 2025
- AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza - March 1st, 2025
- Ultimovacs ASA: Approval and publication of prospectus - March 1st, 2025
- Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous... - March 1st, 2025
- Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting - March 1st, 2025
- InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting - March 1st, 2025
- Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting... - March 1st, 2025
- CORRECTION: Spectral AI Schedules 2024 Fourth Quarter and Full Year Financial Results and Conference Call - March 1st, 2025
- Orion Corporation: Managers’ transactions – Niclas Lindstedt - March 1st, 2025
- ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting - March 1st, 2025
- SRx Health Solutions Granted Final Order to Proceed with the Acquisition by Better Choice Company - March 1st, 2025
- Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ® - March 1st, 2025
- Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older - March 1st, 2025
- Orion Corporation: Managers’ transactions – Outi Vaarala - March 1st, 2025
- Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1 Healthy Volunteer Trial for APG990 and Provide Combination... - March 1st, 2025
- Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy - March 1st, 2025
- Vincerx Pharma Announces Termination of Reverse Merger Term Sheet and Evaluation of Strategic Alternatives - March 1st, 2025
- 4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - March 1st, 2025
- Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update - March 1st, 2025
- Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - March 1st, 2025
- Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference - February 20th, 2025
Global News Feed
Comments Off on Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study |
March 31st, 2025
This author published 6132 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research